High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer

British Journal of Cancer

Volumn 76, Issue 12, 1997, Pages 1646-1651

  Zeimet, A G ^a   Widschwendter, M ^a   Uhl Steidl, M ^a   Muller Holzner E ^a   Daxenbichler, G ^a   Marth, C ^a   Dapunt, O ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

CD44; Ovarian cancer; Prognosis; Serum marker; Tumour immunology

Indexed keywords

CELL ADHESION MOLECULE; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASCITES FLUID; BLOOD LEVEL; CONFORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NORMAL HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030715628     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.611     Document Type: Article

References (26)

1. Arch R, Wirth K, Hofmann M, Punta H, Matzku S, Herrlich P and Zöller M (1992) Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 257: 682-685
2. Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J and Ottensmeier C (1995) CD44 variant expression is a common feature of epithelial ovarian cancer: Lack of association with standard prognostic factors. J Clin Oncol 13: 1912-1921
3. Friedrichs K, Franke F, Lisboa BW, Kügler G, Gille I, Terpe HJ, Hölzel F, Maass H and Günthert U (1995) CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55: 5424-5433
4. Günthert U, Hofmann M, Rudy W, Reber S. Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24
5. Günthert U, Stauder R, Mayer B, Terpe HJ, Finke L and Friedrichs K (1995) Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 24: 19-42
6. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J and Sy MS (1994) Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54: 422-426
7. Heider KH, Dämmrich J, Skroch-Angel P, Müauller-Hermelink HK, Vollmers HP, Herrlich P and Ponta H (1993) Differential expression of CD44 splice variants in intestinal-and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 53: 4197-4203
8. Jalkannen SW, Bargatze RF, De Los Toyos J and Butcher EC (1987) Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal or synovial endothelial cells. J Cell Biol 105: 983-990
9. Kaufmann M, Heider KH, Sinn HP, Von Minckwitz G, Ponta H and Herrlich P (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345: 615-619
10. Khaldoyanidi S, Achtnich M, Hehlmann R and Zöller M (1996) Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression. Leukemia Res 20: 839-851
11. Koretz K, Möller P, Lehnert T, Hinz U, Otto HF and Herfarth C (1995) Effect of CD44v6 on survival in colorectal carcinoma. Lancet 345: 327-328
12. Lein M, Weiß S, Jung K, Schnorr D, Loening S (1996) Soluble CD44 variants in serum of patients with prostate and other urological malignancies. Prostate 29: 334-335
13. Marth C, Weger A, Müller-Holzner E, Zeimet AG, Moncayo-Naveda H. Daxenbichler G, Reibnegger G, Fuchs D, Wachter H and Dapunt O (1993) The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur J Cancer 29A: 1863-1868
14. Marth C, Dreps A, Natoli C, Zeimet AG, Lang T, Widschwendler M, Daxenbichler G, Ullrich A and lacobelli S (1994) Effects of type-I and II interferons on 90K antigen expression in ovarian carcinoma cells. Int J Cancer 59: 808-813
15. Mayer B, Jauch KW, Günthert U, Figdor CG, Schildberg FW, Funke I and Johnson JP (1993) De-novo expression of CD44 and survival in gastric cancer. Lancet 342: 1019-1022
16. Miyake K, Underbill CB, Lesley J and Kincade PW (1990) Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 172: 69-75
17. Mulder JWR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJA and Pals ST (1994) Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344: 1470-1472
18. Ristamäki BR, Joensuu H, Salmi M and Jalkanen S (1994) Serum CD44 in malignant lymphoma: an association with treatment response. Blood 84: 238-243
19. Salles G, Zain M, Jiang WM, Boussiotis VA and Shipp MA (1993) Alternatively spliced CD44 transcripts in diffuse large cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 82: 3539-3547
20. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matzku S and Zoller M (1993) Prevention of tumour metastasis formation by anti-variant CD44. J Exp Med 177: 443-455
21. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A and Kainz C (1995) Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 72: 1494-1497
22. Stauder R, Eisterer W, Thaler J and Günthert U (1995) CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 85: 2885-2899
23. Terpe HJ, Stark H, Prehm P and Günthert U (1994) CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 101: 79-89
24. Uhl-Steidl M, Müller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C and Dapunt O (1995) Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology 52: 400-406
25. Yu Q and Toole BP (1996) A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J Biol Chem 271: 20603-20607
26. Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, Iacobelli S, Dapunt O and Marth C (1996) Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int J Cancer 68: 34-38